Project Details
Description
Phase III Multicenter Randomized trial of CPX-351 (Cytarabine: Daunorubicin) Liposome injections vs Cytarabine and Daunorubicin in Patients 60-75 years of age with untreated high risk (secondary) AML
| Status | Finished |
|---|---|
| Effective start/end date | 10/30/12 → 3/30/20 |
Funding
- CELATOR PHARMACEUTICALS, INC.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.